Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
- NCT03162536 ↗
- Active, not recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Focused
We haven't built an HCP commentary report on NCT03162536 (nemtabrutinib in relapsed or refractory hematologic malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03162536 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Lymphoma, B-Cell; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Richter's Transformation; Follicular Lymphoma; Marginal Zone Lymphoma
- Interventions
- Nemtabrutinib
- Arms
- Phase 1: Dose Escalation and Determination of RP2D · Experimental
- Phase 2: Expansion Cohort A · Experimental
- Phase 2: Expansion Cohort B · Experimental
- Phase 2: Expansion Cohort C · Experimental
- Phase 2: Expansion Cohort D · Experimental
- Phase 2: Expansion Cohort E · Experimental
- Phase 2: Expansion Cohort F · Experimental
- Phase 2: Expansion Cohort G · Experimental
- Phase 2: Expansion Cohort H · Experimental
- Phase 2: Expansion Food Effect Cohort I · Experimental
- Enrollment
- 190 (estimated)
- Primary outcomes
- Phase 1: Number of Participants Experiencing Dose Limiting Toxicity (DLT)
- Phase 1: Number of Participants Who Experienced an Adverse Event (AE)
- Phase 1: Number of Participants Who Discontinued Study Treatment Due to an AE
- Phase 2: Expansion Cohorts A, B & C: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by the Investigator
- Phase 2: Expansion Cohorts A, B, C: ORR per Lugano Classification as Assessed by the Investigator
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Start
- Jun 26, 2017
- Primary completion
- Sep 17, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03162536 · updated Jun 12, 2026
Publications
linked from the registry- Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC. First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. Cancer Discov. 2024 Jan 12;14(1):66-75. doi: 10.1158/2159-8290.CD-23-0670. PubMed 37930156
- Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536. PubMed 34398557